Lung Cancer Awareness Month
Lung Cancer Awareness Month
Focus on Non-Small Cell Lung Cancer
Featured Content
Advent of Hybrid OR Signals Paradigm Shift in Lung Cancer Surgery
One in four cancer deaths are attributable to lung cancer, which is more than breast, prostate, and colon cancers combined, according to the American Cancer Society. One major contributor to the high mortality rate has been the challenge of diagnosing lesions in the lungs.
Lung and Mediastinum
Current Opinion in Oncology
‘Early-stage’ nonsmall cell lung cancer (NSCLC) refers to stage I and stage II disease, and selected cases of stage IIIA disease where complete tumor resection is feasible.
Advanced NSCLC: EGFR Exon 20 Targeting Success
Efficacy and safety outcome findings from the phase I/II open-label multi-center study using a drug targeting the EGFR exon 20 insertion oncogenic driver among patients with advanced non-small cell lung cancer (NSCLC) with and without brain metastases (who had previously been treated with chemotherapy) were reported at the 2019 ASCO Annual Meeting.
Free Download! NSCLC Anatomical Chart
Investigational Antibody Shows Activity in Solid Tumors With Gene Fusions
An investigational bispecific HER2/HER3 antibody leads to clinical responses in patients who harbor fusions in the gene neuregulin 1 (NRG1), including those with metastatic pancreatic ductal adenocarcinoma (PDAC) or metastatic non-small cell lung cancer (NSCLC), according to a new study.
Short-Term Mortality in Stage I NSCLC
American Journal of Clinical Oncology
Although lobectomy is the standard of care in stage I non–small cell lung cancer (NSCLC), medical comorbidities increase surgical risk in elderly patients
Loading